Stock Worth Mentioning: Evoke Pharma Inc Declines A lot Today, Is Now One of The Worst Performer

Stock Worth Mentioning: Evoke Pharma Inc Declines A lot Today, Is Now One of The Worst Performer

The stock of Evoke Pharma Inc (NASDAQ:EVOK) is a huge mover today! The stock decreased 3.54% or $0.08 during the last trading session, hitting $2.18. About 281,007 shares traded hands. Evoke Pharma Inc (NASDAQ:EVOK) has declined 36.63% since March 1, 2016 and is downtrending. It has underperformed by 48.84% the S&P500.
The move comes after 6 months negative chart setup for the $27.78 million company. It was reported on Oct, 4 by Barchart.com. We have $1.92 PT which if reached, will make NASDAQ:EVOK worth $3.33 million less.

Analysts await Evoke Pharma Inc (NASDAQ:EVOK) to report earnings on November, 10. They expect $-0.34 earnings per share, up 19.05% or $0.08 from last year’s $-0.42 per share. After $-0.41 actual earnings per share reported by Evoke Pharma Inc for the previous quarter, Wall Street now forecasts -17.07% EPS growth.

Evoke Pharma Inc (NASDAQ:EVOK) Ratings Coverage

Out of 6 analysts covering Evoke Pharma (NASDAQ:EVOK), 3 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 50% are positive. Evoke Pharma has been the topic of 9 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The company was downgraded on Tuesday, July 19 by Noble Financial. As per Wednesday, March 16, the company rating was initiated by Northland Capital. The firm earned “Hold” rating on Monday, July 18 by Brean Capital. The rating was maintained by Ascendiant Capital with “Buy” on Monday, March 14. On Monday, July 18 the stock rating was downgraded by Rodman & Renshaw to “Neutral”. The stock has “Buy” rating given by Brean Capital on Thursday, August 20. On Friday, October 2 the stock rating was initiated by Rodman & Renshaw with “Buy”. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, October 1 report.

According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 2.67 in Q2 2016. Its up 1.92, from 0.75 in 2016Q1. The ratio increased, as 1 funds sold all Evoke Pharma Inc shares owned while 2 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 1.01 million shares or 161.27% more from 386,180 shares in 2016Q1.
Vanguard Grp has 0% invested in the company for 62,381 shares. Bank Of New York Mellon Corp accumulated 0% or 23,679 shares. Moreover, Tower Ltd Liability Com (Trc) has 0% invested in Evoke Pharma Inc (NASDAQ:EVOK) for 100 shares. Geode Capital owns 15,864 shares or 0% of their US portfolio. Renaissance Techs Ltd Liability Corp holds 18,900 shares or 0% of its portfolio. State Treasurer State Of Michigan accumulated 25,000 shares or 0% of the stock. Knoll Cap Ltd Partnership accumulated 55,660 shares or 0.12% of the stock. Retail Bank Of America De accumulated 2,887 shares or 0% of the stock. Millennium Mgmt Ltd Llc holds 0% of its portfolio in Evoke Pharma Inc (NASDAQ:EVOK) for 60,000 shares. Blackrock Fund Advsr has 0% invested in the company for 12,092 shares. Opaleye Mgmt has invested 2.95% of its portfolio in Evoke Pharma Inc (NASDAQ:EVOK). California Pub Employees Retirement Systems has 36,700 shares for 0% of their US portfolio. Blackrock Inv Mgmt Ltd Llc accumulated 728 shares or 0% of the stock.

Insider Transactions: Since April 6, 2016, the stock had 0 buys, and 8 selling transactions for $1.92 million net activity. $1.62M worth of Evoke Pharma Inc (NASDAQ:EVOK) shares were sold by DOMAIN PARTERS VII L P. The insider DP VII ASSOCIATES LP sold $3,790.

More recent Evoke Pharma Inc (NASDAQ:EVOK) news were published by: Marketwatch.com which released: “Evoke Pharma stock drops 76% after drug’s late-stage topline results miss …” on July 18, 2016. Also Seekingalpha.com published the news titled: “Evoke Pharma: Hop On And Ride The Elevator Higher” on July 31, 2016. 247Wallst.com‘s news article titled: “Is the FDA Changing Its Tune on Evoke Pharma?” with publication date: September 07, 2016 was also an interesting one.

EVOK Company Profile

Evoke Pharma, Inc., incorporated on January 29, 2007, is a specialty pharmaceutical company. The Firm is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment